We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byDarion Waithe
Modified over 2 years ago
Quality by Design—Case Study Vaccines| © 2010 PRTM Proprietary CONFIDENTIAL | 1 Quality by Design – Vaccine Case Study Last year, the CMC-Biotech Working Group (CMC_BWG) completed a case study to exemplify the application of Quality by Design to biopharmaceutical development “A-Mab Case Study” was well received & has served as a substrate to open up the dialogue between industry and regulatory agencies on the challenges of implementing QbD for biotech products Following on this success, facilitators from CMC-BWG have been approached to pull together a similar industry consortium (CMC-VWG) to promote QbD for vaccines Proposed Timeline Contact Vaccine manufacturersJuly 2010 Contact Regulatory AgenciesJuly –August 2010 Set-up NDAs and AgreementsComplete by Sep 15 th Kick- OffOctober 1 st
Quality by Design—Case Study Vaccines| © 2010 PRTM Proprietary CONFIDENTIAL | 2 A Vaccine QbD Case Study: What Is It? Word document co-authored by a consortium of company representatives to promote the implementation of ICH QbD guidelines in vaccine development Will be made available to the public Focus on science and risk-based applications Forward looking—focused on what individuals would like to do in the future versus what they currently do now Multiple perspectives offered as a result of the cross-company and cross-functional interactions Regulators (FDA, PMDA, EMA principals) will be invited to contribute to the case study, but not to endorse it Their insight into QbD application to vaccines would add immensely to its value Targeting top Vaccine Manufacturers To keep the group manageable, the first six companies to sign up by the September 1st deadline will be accepted into the program The Case Study is not… A mock CMC submission or a “Gold Standard” for how things should be done Attempt to receive an endorsement from the regulatory agencies An initiative that requires companies to share intellectual property—specific process operations, real results, etc. The Case Study is not… A mock CMC submission or a “Gold Standard” for how things should be done Attempt to receive an endorsement from the regulatory agencies An initiative that requires companies to share intellectual property—specific process operations, real results, etc.
Quality by Design—Case Study Vaccines| © 2010 PRTM Proprietary CONFIDENTIAL | 3 Contacts Sam Venugopal Principal T+1 650.864.3522 F +1 650.967.6367 M+1 408.396.9649 firstname.lastname@example.org 444 Castro Street Suite 400 Mountain View, CA 94041 U.S.A. www.prtm.com John Berridge Pharmaceutical Ccnsultant T+ 011447971324939 email@example.com Bracklyn, St. Clare Road Walmer Deal CT14 7QB
Workshop Session 3 Questions 1 How would a control strategy look different in a traditional submission vs a QbD submission? How would parameters that are.
Use of Risk-based Approach for Regulating CMC Changes to Approved Applications FDA Public Meeting February 7, 2007.
ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.
Risk-Based CMC Review - OGD Perspective Gary J. Buehler, R.Ph. Director Office of Generic Drugs July 21, 2004 Advisory Committee for Pharmaceutical Science.
Generic Industry’s Perspective on the New GMP Initiative May 21, 2003 Generic Pharmaceutical Association Kenneth Lavin, M.Sc. Director, Regulatory Compliance.
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
Atypical Actives PDA-FDA Conference March 9-10, 2011 David R. Schoneker
INTRODUCTION TO RA.
Manufacturing Subcommittee of the Advisory Committee for Pharmaceutical Science July 20-21, 2004 Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.
1 An Update on ICH Guideline Q8 – Pharmaceutical Development FDA Advisory Committee for Pharmaceutical Science: 5 Oct 2006 Dr John C Berridge Senior Regulatory.
ICH Quality Topics Update
FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.
Executive summary prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.
Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,
FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.
1 Revisions to 21 CFR Supplements and Other Changes to an Approved Application PhRMA Perspective FDA Public Meeting – 7 Feb 2007.
PhRMA Perspective on FDA Final Report FDA Advisory Committee on Pharmaceutical Sciences October 20, 2004 G.P. Migliaccio, Pfizer Inc.
VALIDATION OF COMPUTERISED SYSTEMS IN THE PHARMACEUTICAL INDUSTRY Matt Safi Product manager.
Perspectives on New Paradigms of Risk and Compliance in Pharmaceutical Development: Quality by Design, PAT, and Design Space David J. Cummings OPS Quality.
10:00 A.M. – Noon 7 June 2004 ICH Quality Plenary Meeting.
CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. THE PRACTICE OF REGULATORY INTELLIGENCE: CASE STUDIES OMICS 5 th International Pharmaceutical.
Pharmaceuticals and Global Health: Successes, Challenges and Outlook 19. July 2013, University of Sussex Thomas B. Cueni, Secretary General Interpharma.
Doc.: IEEE f Submission IEEE f March 2010 Tim Harrington, Zebra Enterprise SolutionsSlide 1 Project: IEEE P
ITFG/IPAC Collaboration Introduction OVERVIEW OF ITFG/IPAC COLLABORATION Presented by: Harris Cummings, PhD 26 April 2000 Rockville, MD.
Scientific Data for Evidence- Based Drug Regulation Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research Food and Drug Administration.
Mary Ellen Turner MD, MPH Vice-President
Slide 1 The contribution of a world-class regulatory environment to the future of the industry in Ireland Pat O’Mahony Chief Executive, Irish Medicines.
Doc.: b Submission January 2006 Marco Naeve, Eaton Corp. Slide 1 Project: IEEE P Working Group for Wireless Personal Area Networks.
17 September 2007ISO TC215 WG6 Brisbane1 Identification of Medicinal Products & Pharmacovigilance Task Forces.
Implementing Shared Inspection Management Systems Insights from recent WBG research John R. Wille WBG Investment Climate Advisory Services Amman, Jordan.
Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.
1 Nanoscale Materials Stewardship Program Environmental Summit May 20, 2008 Jim Alwood Chemical Control Division Office of Pollution Prevention and Toxics.
Welcome to Kellogg Career Management Center Staff and Roles Programs and Student Overview Off Campus Opportunities Recruiting Timeline, Key Dates and.
Top Business IT Challenges of 2016
Catalysts for enactment of PDUFA Amendments to FD&C Act Origin of modern drug development process Requirement that drugs be shown to be safe.
IDMP Overview December 2015.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
4 th Kitasato-Harvard Symposium: Summary and Conclusions Stephen Lagakos Harvard School of Public Health.
Victoria Cassens, Purdue University Accepted Labels State Tracking and Repository: ALSTAR.
CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. REGULATORY INTELLIGENCE: INDUSTRY’S BEST PRACTICE OMICS 5 th International Pharmaceutical.
Strategy for Partnerships And Innovation. My Goals Today University of Calgary Engage Grants Information Session February 26, 2015 Discuss Engage and.
Biopharmaceutical Regulatory Requirements 40. Marketing Authorization for New Chemical Entities Health Canada’s (HC) Therapeutic Products Directorate.
Consulting for Life Sciences 1 Confidential October 14, 2014 Strategic Science and Technology Capabilities Discussion
6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Part 11 Public Meeting PEERS Questions & Responses The opinions expressed here belong to PEERS members and not the corporate entities with which they are.
Collaboration between FDA and EMA
Biotech Regulations Modified by Georgia Agricultural Education Curriculum Office June, 2002.
Challenges and Opportunities in Enhancement of the CMC Section of NDAs: Quality – by - Design Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.
Chemical Industries Council of Malaysia Responsible Care APEC CHEMICAL DIALOGUE 9th Asia Pacific Responsible Care Conference November 16, 2005 * EDSA.
© 2017 SlidePlayer.com Inc. All rights reserved.